<SEC-DOCUMENT>0001213900-26-000794.txt : 20260105
<SEC-HEADER>0001213900-26-000794.hdr.sgml : 20260105
<ACCEPTANCE-DATETIME>20260105092525
ACCESSION NUMBER:		0001213900-26-000794
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20260105
FILED AS OF DATE:		20260105
DATE AS OF CHANGE:		20260105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inspira Technologies OXY B.H.N. Ltd
		CENTRAL INDEX KEY:			0001837493
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40303
		FILM NUMBER:		26504164

	BUSINESS ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
		BUSINESS PHONE:		972-9-9664488

	MAIL ADDRESS:	
		STREET 1:		HATIDHAR 2
		STREET 2:		11TH FLOOR
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4366504
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0271764-6k_inspira.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>For the Month of January 2026 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number: 001-40303</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Translation of registrant&rsquo;s name into
English)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>2 Ha-Tidhar St.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Ra&rsquo;anana 4366504, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Address of principal executive office)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
files or will file annual reports under cover of Form 20-F or Form 40-F:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#9746;&nbsp;Form 20-F&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#9744;&nbsp;Form
40-F</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Term Sheet</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 5, 2026, Inspira
Technologies Oxy B.H.N. Ltd. (the &ldquo;Company&rdquo;) entered into a non-binding term sheet (the &ldquo;Term Sheet&rdquo;) with a company
(the &ldquo;Target&rdquo;) to acquire the Target&rsquo;s liquid biopsy business in exchange for 40% of the Company&rsquo;s issued and
outstanding share capital on a fully diluted basis. As a part of the acquisition, the Company will obtain a $15 million equity investment
(the &ldquo;Equity Investment&rdquo;) at a&nbsp;Company pre-money valuation of $180 million or at such valuation as may be expressly agreed
by the parties in the negotiated definitive agreement to acquire Target&rsquo;s liquid biopsy business (the &ldquo;Purchase Agreement&rdquo;).
The closings of the Equity Investment and the Purchase Agreement are intended to happen concurrently. Existing shareholders of the Company
as of a record date preceding the closing of the Purchase Agreement and the Equity Investment, or such other date agreed by the parties,
shall receive contingent value rights to net proceeds from the sale of the current business assets and/or business activity (the &ldquo;Legacy
Assets&rdquo;) of the Company to a third party. The Company intends to use up to $12 million from the net proceeds of the Equity Investment
to fund the ongoing operations of its Legacy Assets, unless and until it sells the Legacy Assets. If the funding of the Legacy Assets
exceeds $5 million in the aggregate, the Target may be entitled to receive the amount exceeding such $5 million from any net proceeds
of a sale of the Legacy Assets, including up to the entirety of the aggregate net proceeds received from the sale of the Legacy Assets
(but in any case no more than such net proceeds), following a successful sale of the Legacy Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Senior Convertible Debenture</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the Term
Sheet, on January 5, 2026, the Company entered into a binding senior convertible debenture (the &ldquo;Debenture&rdquo;) with the Target,
whereby the Company agreed to lend the Target a principal amount of $1 million. The Debenture will bear interest at a 10% annual rate,
provided, however, that in case of an Event of Default (as defined in the Debenture), the annual interest rate shall increase to 18%,
retroactively as of the original issue date. The Target may prepay any portion of the principal amount of the Debenture without need for
a prior written consent of the Company. Any payment thereof (including any partial payment) shall first be made on account of outstanding
interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Debenture matures on the
date that is 180 days from January 5, 2026, on or such earlier date where (i) the Purchase Agreement has not been entered into within
60 days from January 5, 2026, (ii) if there is a change in control of the Target (including, without limitations, changes in the composition
of the Target&rsquo;s board of directors where the majority of board members (excluding the external members) holding office on the date
hereof, cease to hold office, then the date of such change in control (the &ldquo;Maturity Date&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the original issue
date of the Debenture, but no later than the lapse of the Maturity Date, unless otherwise extended by mutual consent of the Company and
the Target, if the closing of the Equity Investment, Purchase Agreement and sale of the Legacy Assets (collectively, the &ldquo;Transaction&rdquo;)
shall have occurred, at the time of such closing, all amounts under the Debenture shall either, according to the discretion of Target
(i) be offset from any consideration payable to Target by the Company in connection with the Asset Purchase Agreement, (ii) or alternatively,
at Target&rsquo;s sole discretion (provided that the interest portion shall be paid in cash to the Company), the Target shall repay the
outstanding amounts under the Debenture. Subject to the consummation of the Purchase Agreement, the Company and Target may further agree
to redeem the outstanding principal amount under the Debenture by issuing the most senior class of securities of the entity owning the
Target&rsquo;s liquid biopsy business at the closing of the Asset Purchase Agreement (insofar as the Asset Purchase Agreement is consummated
by way of a spin-off or a similar transaction), at a price per share based on a pre-money valuation of $45 million of such entity, and
the Target will concurrently make cash payment of any interest accrued thereof, to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Target (and the Company,
in case that the Debenture has not been fully discharged by the Maturity Date, or such earlier time in case of an Event of Default which
is continuing) (each, as applicable, an &ldquo;Initiating Party&rdquo;) may, at any time prior to the full discharge of the Debenture,
convert, in whole (unless otherwise agreed by the Company to convert only part of the outstanding principal amount), the outstanding principal
amount (and/or accrued interest &ndash; if instructed by the Company) of the Debenture, into ordinary shares, NIS 0.001 par value per
share, of the Target, at a conversion price of NIS 0.30 per share (or, if applicable, the then applicable minimum effective conversion
price permitted by the Tel Aviv Stock Exchange (the &ldquo;TASE&rdquo;)); provided that, in no event shall such conversion price be less
than the minimum effective share price permitted by the TASE regulations and bylaws. Any conversion under the Debenture shall be subject
to the approval of the TASE for the registration of the shares to be issued as a result of such conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is subject to an ownership limitation
cap of 19.99% (the &ldquo;Ownership Limitation&rdquo;), and the Company shall not be entitled to convert any portion of the Debenture
in excess of the Ownership Limitation (the number of Target&rsquo;s ordinary shares to be converted shall not exceed 27,783,367 of the
Target&rsquo;s ordinary shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Debenture contains certain prerequisites, such
as corporate approval and TASE approval of the ordinary shares to be issued upon conversion of the Debenture, and customary representations,
warranties and covenants of the Company and Target, including receipt of $5 million by the Company pursuant to the Standby Equity Purchase
Agreement, dated December 12, 2025, by and between the Company and YA II PN, Ltd. The Debenture will be deemed issued at the signing,
however, the Company&rsquo;s obligation to pay $1 million is subject to the satisfaction of the prerequisites.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The foregoing description of the Debenture does
not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference
to the full text of the form of such agreement, a copy of which is attached hereto as Exhibit 4.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Press Release </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 5, 2026, the Company issued a press
release titled &ldquo;Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent
$15 Million Investment at $180 Million Valuation,&rdquo; a copy of which is furnished as Exhibit 99.1 to this Report <FONT STYLE="background-color: white">of
Foreign Private Issuer on Form 6-K (this &ldquo;Report&rdquo;)</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="background-color: white">This
Report, with the exception of the second paragraph of the press release attached hereto as Exhibit 99.1, is incorpora</FONT>ted <FONT STYLE="background-color: white">by
reference into the Company&rsquo;s Registration Statements on Form&nbsp;F-3 (Registration Nos. </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390025004023/ea0227763-f3_inspira.htm"><FONT STYLE="background-color: white">333-284308</FONT></A>
<FONT STYLE="background-color: white">and </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390025072618/ea0251967-f3_inspira.htm"><FONT STYLE="background-color: white">333-289324</FONT></A><FONT STYLE="background-color: white">)
and Form&nbsp;S-8 (Registration Nos. </FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390021044780/ea146415-s8_inspiratech.htm"><FONT STYLE="background-color: white">333-259057</FONT></A><FONT STYLE="background-color: white">,
</FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390024023044/ea0201791-s8_inspira.htm"><FONT STYLE="background-color: white">333-277980</FONT></A>,
<A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390025020699/ea0233153-s8_inspira.htm">333-285565</A> <FONT STYLE="background-color: white">and
</FONT><A HREF="https://www.sec.gov/Archives/edgar/data/1837493/000121390025086563/ea0254938-s8_inspira.htm"><FONT STYLE="background-color: white">333-290162</FONT></A><FONT STYLE="background-color: white">),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>Forward-Looking
Statements</B>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">This
Report contains forward-looking statements within the meaning of the &ldquo;safe harbor&rdquo; provisions of the Private Securities Litigation
Reform Act of 1995 and other federal securities laws. For example, the Company is using forward-looking statements when it discusses the
entry into and the closings of the Purchase Agreement and the Equity Investment and the timings thereof, the Company&rsquo;s pre-money
valuation for the Equity Investment and the expected use of the proceeds from the Equity Investment. All statements other than statements
of historical facts included in this Report are forward-looking statements. Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on the Company&rsquo;s current beliefs, expectations and assumptions regarding
the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.
Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances
that are difficult to predict and many of which are outside of the Company&rsquo;s control. The Company&rsquo;s actual results and financial
condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these
forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those
indicated in the forward-looking statements include the risks and uncertainties described in the Company&rsquo;s annual report on Form
20-F for the year ended December 31, 2024, filed with the SEC on March 10, 2025, and the Company&rsquo;s other filings with the SEC. The
Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time
to time, whether as a result of new information, future developments or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: white">
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 9%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; vertical-align: bottom; width: 90%; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT>*</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea027176401ex4-1_inspira.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Debenture.</FONT></A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><A HREF="ea027176401ex99-1_inspira.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on January 5, 2026, titled &ldquo;Inspira Signs Term Sheet for Acquisition of Advanced Liquid Biopsy Cancer Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation.&rdquo;&nbsp;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Certain identified information in the exhibit has been excluded
from the exhibit because it is both (i) not material and (ii) is the type that Inspira Technologies Oxy B.H.N. Ltd. treats as private
or confidential.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inspira Technologies Oxy B.H.N. Ltd.</B></FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: January 5, 2026</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dagi Ben-Noon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea027176401ex4-1_inspira.htm
<DESCRIPTION>FORM OF DEBENTURE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT,
MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT INSPIRA TECHNOLOGIES
OXY B.H.N. LTD. TREATS AS PRIVATE OR CONFIDENTIAL.&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES INTO
WHICH THIS SECURITY IS REDEEMABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Original Issue Date: ______, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">$1,000,000<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>SENIOR
CONVERTIBLE DEBENTURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS SENIOR CONVERTIBLE DEBENTURE
(the &ldquo;<U>Debenture</U>&rdquo;) is validly issued pursuant to the contemplated transactions between Inspira Technologies Oxy B.H.N.
Ltd. and/or any of its subsidiaries ( &ldquo;<U>Inspira</U>&rdquo;) and [***] (the &ldquo;<U>Company</U>&rdquo;). The Debenture is issued
in connection with the provision of the $1,000,000 principal amount by Inspira to the Company in view of a contemplated transaction between
Inspira and the Company, <I>inter-alia</I>, for the issuance of Inspira shares to the Company in consideration of the sale and conveyance
of a certain asset of the Company, as generally reflected under that certain Term-Sheet entered between the Company and Inspira on [______],
2026 (the &ldquo;<U>Term-Sheet</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">FOR VALUE RECEIVED, the Company
promises to repay to Inspira (the &ldquo;<U>Holder</U>&rdquo;) either in cash or by conversion into the Company&rsquo;s Ordinary Shares, the
principal and all accrued interest (and other costs referenced herein) under this Debenture, in accordance with the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Debenture is subject
to the following additional provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&nbsp;<U>Definitions</U>.
For the purposes hereof, in addition to the terms defined elsewhere in this Debenture, (a) capitalized terms not otherwise defined herein
shall have the meanings set forth in the Term Sheet and (b) the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Asset
Purchase Agreement</U>&rdquo; means the agreement for the purchase of Company&rsquo;s liquid biopsy business by Inspira, within the course
of the Transaction, or any other agreement entered to capture the same result in connection with the Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bankruptcy
Event</U>&rdquo; means any of the following events: (a) the Company or any Significant Subsidiary thereof commences a case or other proceeding
under any bankruptcy, arrangement, , dissolution, insolvency or liquidation or similar law of any jurisdiction relating to the Company
or any Significant Subsidiary thereof,, (b) there is commenced against the Company or any Significant Subsidiary thereof any such case
or proceeding that is not dismissed within 90 days after commencement, (c) the Company or any Significant Subsidiary thereof is adjudicated
by a competent court insolvent or bankrupt or any order of relief or other order approving any such case or proceeding is entered(d) the
Company or any Significant Subsidiary thereof suffers any appointment of any custodian or the like for it or any substantial part of its
property that is not discharged or stayed within 90 calendar days after such appointment, (e) the Company or any Significant Subsidiary
thereof makes a general assignment for the benefit of creditors, (f) the Company or any Significant Subsidiary thereof calls a meeting
of its creditors with a view to arranging a composition, adjustment or restructuring of its debts, (g) the Company or any Significant
Subsidiary thereof admits in writing that it is generally unable to pay its debts as they become due, (h) the Company or any Significant
Subsidiary thereof, by any act or failure to act, expressly indicates its consent to, approval of any of the foregoing or takes any corporate
or other action for the purpose of effecting any of the foregoing. For avoidance of doubt, in relation to any person, any reference to
a Bankruptcy Event shall also include reference to: (i) liquidation, winding-up, dissolution, administration (ii), freeze order, stay
of proceedings (<I>Ikuv Halichim</I>&rdquo;) (or other similar remedy) or an order for commencing proceedings (<I>Tzav le-Ptichat Halichim</I>)
concerning Company&rsquo;s insolvency, or an order for liquidation (<I>Tzav Piruk)</I>; or (iii) a debt arrangement (&ldquo;<I>Hesder
Chov</I>&rdquo;); or (iv) the recognition of a foreign proceeding with respect to an insolvency of a company (&ldquo;<I>Hakara be Halich
Zar</I>&rdquo;), as such terms are understood under the Insolvency Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction</U>&rdquo; means the Transaction
as defined in the Term Sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business Day</U>&rdquo; means any day
except any Saturday, any Sunday, any day which is a federal legal holiday in the United States, a legal holiday in the State of Israel,
or any day on which banking institutions in the State of New York or the State of Israel are authorized or required by law or other governmental
action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Fundamental Transaction</U>&rdquo; shall
mean, except with respect to the Transaction, any transaction whereby (i) the Company, directly or indirectly, in one or more related
transactions effects any business combination, merger or consolidation of the Company with or into another Person, (ii) the Company, directly
or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of
its assets and/or securities in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or
exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Ordinary Shares are permitted to sell,
tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding
Ordinary Shares, (iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization
or recapitalization of the Ordinary Shares or any compulsory share exchange pursuant to which the Ordinary Shares is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions
consummates a share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization,
spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the outstanding Ordinary Shares
(not including any Ordinary Shares held by the other Person or other Persons making or party to, or associated or affiliated with the
other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental
Transaction</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Indebtedness</U>&rdquo;
means (x) any Liabilities for borrowed money and/or amounts owed by the Company, (y) all guaranties, endorsements and other contingent
obligations in respect of indebtedness of others to third parties, whether or not the same are or should be reflected in the Company&rsquo;s
consolidated balance sheet (or the notes thereto).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Maturity
Date</U>&rdquo; shall mean 180 days from the date hereof, on or such earlier date where (i) the Asset Purchase Agreement has not been
entered into within 60 days from the date hereof, (ii) there has been a change in control in the Company (including, without limitations,
changes in the composition of the Company&rsquo;s Board of Directors where the majority of Board members (excluding the external members)
holding office on the date hereof, cease to hold office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liabilities</U>&rdquo;
means any and all debts, credit lines, credit facilities, liabilities, payables, commitments, obligations, and the costs or expenses related
thereto, whether absolute or contingent, liquidated or unliquidated, secured or unsecured, matured or unmatured, determined or undeterminable,
and whether or not accrued or reflected on a balance sheet, including those arising under any applicable law, agreement and/or legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Lien&rdquo;</U>
shall mean a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right and/or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Ordinary
Share</U>&rdquo; means the Company&rsquo;s Ordinary Share, par value NIS 0.001.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permitted
Indebtedness</U>&rdquo; means, subject always to any other obligation and/or covenant of the Company hereunder, (a) the indebtedness evidenced
by the Debenture and/or any subsequent debenture and/or debt instruments entered between Company and Holder, (b) the Indebtedness existing
on the Original Issue Date of USD 1.15M (for current Liabilities by the Company and its subsidiary, net of USD 1.25M of deferred income
on the date hereof) and (c) any Indebtedness incurred in the ordinary course of business following the Original Issue date, which shall
not exceed, in the aggregate $500,000, without Inspira&rsquo;s prior written consent. (d) any loans or credit facilities provided by the
Company&rsquo;s Subsidiaries to the Company. (e) Any existing line of credit or credit facility available to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Permitted
Lien</U>&rdquo; means, (a) Liens for taxes, assessments and other governmental charges or levies not yet due or Liens for taxes, being
contested in good faith and by appropriate proceedings for which adequate reserves, (b) Liens incurred prior to the Original Issue Date
in connection with Permitted Indebtedness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Significant
Subsidiary</U>&rdquo; or &ldquo;<U>Subsidiary</U>&rdquo; means any subsidiary of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>TASE</U>&rdquo;
means the Tel-Aviv Stock Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><U>Section 2</U>.&nbsp;<U>Interest</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Interest</U>.
The outstanding principal amount of this Debenture shall bear interest on the aggregate unredeemed and then outstanding amount of this
Debenture at the rate of 10% per annum; provided, however, that in case of an Event of Default, the interest rate shall be at the rate
of 18%, retroactively as of the Original Issue Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="text-decoration: none">b) </FONT><U>Interest
Calculations</U>. Interest shall be calculated on the basis of a 365-day year, and shall accrue quarterly commencing on the Original
Issue Date until payment or conversion in full of this Debenture together with all accrued and unpaid interest. Notwithstanding
anything to the contrary herein, except with Inspira&rsquo;s prior written consent, any repayment of outstanding interest shall be
made in cash by the Company.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Prepayment;
Partial Payment</U>. The Company may prepay any portion of the principal amount of this Debenture (without need for the prior
written consent of the Holder). Any payment thereof (including any partial payment) shall first be made on account of outstanding
interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3.</U>&nbsp;<U>Redemption;
Conversion</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a) <U>Redemption.</U>
Insofar as following the Original Issue Date, but no later than the lapse of the Maturity Date, unless otherwise extended by mutual consent
of the Company and Inspira, the closing of the Transaction shall have occurred, at the time of such closing, all amounts under this Debenture
shall either, according to the discretion of the Company (i) be offset from any consideration payable to Company by Inspira in connection
with the Asset Purchase Agreement, or alternatively, at Company&rsquo;s sole discretion (provided that the interest portion shall be paid in
cash to Inspira), (ii) Company shall repay the outstanding amounts under this Debenture. The Company and Inspira may further agree (with
Inspira&rsquo;s consent not being unreasonably delayed or withheld), to redeem the outstanding principal amount under this Debenture by
for the issuance of the most senior class of securities of the entity owning Company&rsquo;s liquid biopsy business at the closing of
the Asset Purchase Agreement (insofar as the Asset Purchase Agreement is consummated by way of a spin-off or a similar transaction), at
a price per share based on a pre-money valuation of $45,000,000 of such entity, and that Company will concurrently make cash payment of
any interest accrued thereof, to Inspira.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b) <U>Conversion</U>.
Company (and Inspira, in case that this Debenture has not been fully discharged by the Maturity Date, or such earlier time in case of
an Event of Default which is continuing) (each, as applicable: an &ldquo;<B>Initiating Party</B>&rdquo;) may, at any time prior to the
full discharge of this Debenture, convert, in whole (unless otherwise agreed by Inspira to convert only part of the outstanding principal
amount), the outstanding principal amount (and/or accrued interest &ndash; if instructed by Inspira) on this Debenture, into Ordinary
Shares of the Company, at a conversion price of NIS 0.3 per share (or, if applicable, the then applicable minimum effective conversion
price permitted by TASE) ; provided that, in no event shall such conversion price be less than the minimum effective share price permitted
by TASE regulations and bylaws. The Initiating Party shall, in case such Initiating Party elects to convert any amounts under this Debenture,
deliver the other party with a written notice specifying such conversion (the &ldquo;<U>Conversion Notice</U>&rdquo;), and the Company
shall affect such conversion within 10 (ten) Business days from the date of the Conversion Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c) Any conversion
under this Debenture shall be subject to the approval of the TASE for the registration of the shares to be issued as a result of such
conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(d) Notwithstanding
anything to the contrary in this Debenture, the number of the Company&rsquo;s shares to be converted to Inspira (the &ldquo;<B>Total Allocated
Shares</B>&rdquo;) shall not exceed 27,783,367 Company&rsquo;s shares (i.e., shall not exceed 19.99% of the Company&rsquo;s issued share capital
prior to the allocation pursuant to this Debenture). It is hereby clarified that if the Company carries out a reverse split or a stock
split, an adjustment shall be made to the above maximum number of shares in connection with such reverse split or stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4.Company Covenants
and Holder Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">As long as any portion of
this Debenture remains outstanding, without the prior written consent of Holder, the Company shall not, and shall not permit any of the
Subsidiaries to, directly or indirectly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) other than Permitted
Indebtedness, enter into, create, incur, assume, guarantee or suffer to exist any indebtedness for borrowed money of any kind, including,
but not limited to, a guarantee, on or with respect to any of its property or assets now owned or hereafter acquired or any interest therein
or any income or profits therefrom, outside the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) other than Permitted
Liens, enter into, create, incur, assume or suffer to exist any Liens of any kind, on or with respect to any of its property or assets
now owned or hereafter acquired or any interest therein or any income or profits therefrom;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) repay,
repurchase or offer to repay, repurchase or otherwise acquire its Ordinary Shares;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) repay, repurchase
or offer to repay, repurchase or otherwise acquire any Indebtedness, other than Permitted Indebtedness;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) pay cash dividends
or distributions on any equity securities of the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) enter into any
agreement with respect to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Section 5</U>.&nbsp;<U>Events of
Default</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) &ldquo;<U>Event
of Default</U>&rdquo; means, wherever used herein, any of the following events (whatever the reason for such event and whether such event
shall be voluntary or involuntary or effected by operation of law or pursuant to any judgment, decree or order of any court, or any order,
rule or regulation of any administrative or governmental body):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">i. any
default in the payment of (A) the principal amount of any Debenture or (B) interest, liquidated damages and other amounts owing to a Holder
on the Debenture, as and when the same shall become due and payable (whether on Maturity Date or by acceleration or otherwise), which
default, solely in the case of an interest payment or other default under clause (B) above, is not cured within 21 Business Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">ii. the
Company shall fail to observe or perform any representation, covenant or agreement contained in the Debenture, which failure is not cured,
if possible to cure, within the earlier to occur of (A) &lsquo;ten (10) Business Days after notice of such failure sent by the Holder or by
any other Holder to the Company and (B) ten (10) Business Days after the Company has become or should have become aware of such failure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 56.7pt"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">iii.
any breach of any covenant hereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">iv. any
representation or warranty made in this Debenture, any written statement pursuant hereto or thereto or any other report, financial statement
or certificate made or delivered to the Holder or any other Holder shall be untrue or incorrect in any material respect as of the date
when made or deemed made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">v. the
Company shall be subject to a Bankruptcy Event;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">vi. the
Company shall default on any of its material obligations under any mortgage, credit agreement or other facility, indenture agreement,
factoring agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0.75in">vii. any
material breach by the Company of the representations and Covenants prescribed under section 6 below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.75in">Company shall inform
Inspira immediately upon becoming aware of an Event of Default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Insofar as a foregoing event deemed
as an Event of Default shall have occurred (and does not contain a cure period in the respective subsection), the Company shall have ten
(10) Business Days to cure such default (to the extent such default can be reasonably cured).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>Remedies
Upon Event of Default</U>. If any Event of Default occurs, the outstanding principal amount of this Debenture, plus accrued but unpaid
interest and liquidated damages (but only to the extent of reasonable and documented expenses), shall become, at the Holder&rsquo;s election,
immediately due and payable, or otherwise converted into Company&rsquo;s Ordinary Shares based on the mechanism set forth in Section 3(b),
at Inspira&rsquo;s discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Section 6. Representations and Covenants
of Company. </U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company hereby warrants,
represents and undertakes towards Inspira that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) The Company is
duly organized and validly existing under the laws of the State of Israel, and has full corporate power and authority to own, lease and
operate its properties and assets and to conduct its business as now being conducted and as currently proposed to be conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) (i) all corporate
action on the part of the Company necessary for the authorization, execution, delivery, and performance of all of the Company&rsquo;s obligations
under this Debenture has been taken, excluding approval of this Debenture and the Term Sheet by the Board of Directors of the Company.
As detailed in Section 8 (ii) this Debenture, when executed and delivered by or on behalf of the Company, shall constitute the valid and
legally binding obligations of the Company, legally enforceable against the Company in accordance with its terms; and (iii) no consent,
approval, order, license, permit, action by, or authorization of or designation, declaration, or filing with any governmental authority
(except for securing TASE approval and other ISA filing and approvals which will be secured prior to the remittance of the principal amount
by Inspira, if applicable) on the part of the Company is required that has not been, obtained by the Company prior to the date hereof,
in connection with the valid execution, delivery and performance of this Debenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) So long as the
Debenture remains outstanding, other than Permitted Liens, (i) no Liens shall be imposed by the Company and/or with their permission except
for a Permitted Lien (ii) no Indebtedness except for Permitted Indebtedness shall be incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) So long as this
Debenture remains outstanding, Company shall not take any action nor make any claim against the validity of this Debenture, and shall
not, whether by amending its Articles of Association nor any other action, act to evade from taking any action required hereunder in order
to protect Holder&rsquo;s rights herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(e) The Company
shall conduct its business in the ordinary course, and consistent with past practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) The Company shall
only use the proceeds derived from this Debenture to for expenses incurred in the ordinary course of the Company&rsquo;s business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(g) the Company
shall maintain out of its authorized share capital, sufficient number of Ordinary Shares required to enable the conversion of this Debenture
in accordance with its terms, free and clear of any Liens.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Section 7. <U>Representations of Inspira.
</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Inspira hereby warrants, represents
and undertakes towards Company that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) Inspira is duly
organized and validly existing under the laws of the State of Israel, and has full corporate power and authority to own, lease and operate
its properties and assets and to conduct its business as now being conducted and as currently proposed to be conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) all corporate
action on the part of Inspira necessary for the authorization, execution, delivery, and performance of all of the Inspira&rsquo;s obligations
under this Debenture has been taken; (ii) this Debenture, when executed and delivered by or on behalf of Inspira, shall constitute the
valid and legally binding obligations of Inspira, legally enforceable against Inspira in accordance with its terms; (iii) No consent,
approval, order, license, permit, action by, or authorization of or designation, declaration, or filing with any governmental authority
(except for ISA filings, if applicable) on the part of Inspira is required that has not been, obtained by the Inspira prior to the date
hereof, in connection with the valid execution, delivery and performance of this Debenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) So long as this
Debenture remains outstanding, Inspira shall not take any action nor make any claim against the validity of this Debenture, and shall
not, whether by amending its Articles of Association nor any other action, act to evade from taking any action required hereunder in order
to protect Company&rsquo;s rights herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) There are no
agreements, whether written or oral, between the Inspira and any shareholder of the Company, relating to the purchase or sale of the Company&rsquo;s
securities or relating to voting rights therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) Inspira acknowledges
and confirms that the securities offered pursuant to this Debenture shall be subject to restrictions on resale in accordance with Section
15C of the Israeli Securities Law and the regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) Inspira represents
and warrants that it does not hold, directly or indirectly, any additional securities of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Section 8. Prerequisites.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">For avoidance of
doubt, Inspira&rsquo;s obligations to make available to the Company the principal amount per which this Debenture is issued shall be contingent
upon the following conditions, all to be satisfied within 45 days from the date of execution of this Debenture. For the avoidance of doubt,
if any of the conditions set forth in clauses 8(a) through 8(c) have not been satisfied (or waived, to the extent permitted herein) within
the applicable period, then this Debenture shall automatically terminate and be of no further force or effect, without any liability to
either party, unless the parties shall have expressly agreed in writing to extend such period or otherwise waive or amend such conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 20.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) Approval
of the TASE for the Issuance of the Total Allocated Shares be issued under this Debenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 20.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) Inspira&rsquo;s
receipt of an investment in the aggregate amount of USD 5,000,000. through a Stand By Equity Purchase Agreement (SEPA) from Yorkvill.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 20.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)
Approval of this Debenture and the Term Sheet by the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><U>Section 9</U>.&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exchange Rate</U>.
In case that any payment herein is made in US dollars and the conversion price is calculated on an NIS basis, then for such purpose the
USD:NIS exchange rate shall be the exchange rate applicable published by the Bank of Israel on the date of the Conversion Notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>Notices</U>.
All notices and other communications required or permitted hereunder to be given to a party to this Debenture shall be in writing and
shall be sent by email or mailed by registered or certified airmail, postage prepaid, or otherwise delivered by hand or by messenger,
to the respective address set forth in the preamble to this Debenture, or such other address with respect to a party as such party shall
notify each other party in writing as above provided. Any notice sent in accordance with this Section hall be effective:; (i) if sent
by messenger, upon delivery; and (ii) if sent via email, upon transmission and electronic confirmation of receipt or, if transmitted and
received on a non-Business day on the first Business Day following transmission and electronic confirmation of receipt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>No Offset</U>.
Any repayment (including conversion) of any amount under this Debenture shall be made without offset by the Company. Company may withhold
any amounts it is legally required to under law, provided that Company shall first allow Inspira to present a valid tax certificate of
either (i) providing a full exemption of tax withholding, or (ii) setting a reduced tax withholding rate (the &ldquo;Valid Tax Certificate&rdquo;).
The Company shall act in accordance with the provisions of the Valid Tax certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Governing
Law</U>. This Debenture shall be governed and construed in accordance with the laws of the State of Israel without reference to its conflict
of laws rules. The competent court of Tel Aviv-Jaffa shall have exclusive jurisdiction in respect of all disputes arising or related to
this Debenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;<U>Waiver</U>.
Any waiver by the Company or the Holder of a breach of any provision of this Debenture shall not operate as or be construed to be a waiver
of any other breach of such provision or of any breach of any other provision of this Debenture. The failure of the Company or the Holder
to insist upon strict adherence to any term of this Debenture on one or more occasions shall not be considered a waiver or deprive that
party of the right thereafter to insist upon strict adherence to that term or any other term of this Debenture on any other occasion.
Any waiver by the Company or the Holder must be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;<U>Severability</U>.
If any provision of this Debenture is held by a court of competent jurisdiction to be unenforceable under applicable law, then such provision
shall be excluded from this Debenture and the remainder of this Debenture shall be interpreted as if such provision were so excluded and
shall be enforceable in accordance with its terms; provided, however, that in such event this Debenture shall be interpreted so as to
give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning and intention of the excluded provision
as determined by such court of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)&nbsp;<U>Remedies.</U>
The remedies provided in this Debenture shall be cumulative and in addition to all other remedies available under this Debenture or
otherwise, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall
limit the each party&rsquo;s right to pursue actual and consequential damages for any failure by the other party to comply with the
terms of this Debenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)&nbsp;<U>Headings</U>.
The headings contained herein are for convenience only, do not constitute a part of this Debenture and shall not be deemed to limit or
affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i) <U>No Transfer</U>.
Inspira understands and confirms that this Debenture may not be sold, transferred, assigned, pledged, or otherwise disposed of without
the prior written approval of the Company and subject to any applicable law and regulation. For the avoidance of doubt, the Company shall
not unreasonably withhold or delay such approval, and any refusal must be based on reasonable grounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(j) Each party acknowledges
that it has been represented by independent counsel throughout all of the negotiations which preceded the execution of this Debenture
and the Term Sheet, and that it has executed this Debenture with the consent and upon the advice of such independent counsel. Each party
further acknowledges that this Debenture have been drafted as a result of negotiations between the parties, and therefore, no provision
shall be construed so as to favor or disfavor either party hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(k) In accordance with the TASE regulations
and the directives thereunder, the Debenture shall not be convertible on the record date for a bonus share distribution, a rights offering,
a dividend distribution, a capital consolidation, a capital split, or a capital reduction (each of the foregoing referred to herein as
a &ldquo;Corporate Event&rdquo;). It is further clarified that if the ex-date of a Corporate Event occurs before the record date of such
Corporate Event, no conversion shall be permitted on such ex-date.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">*********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
have caused this Debenture to be duly executed by a duly authorized officer as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="padding-right: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inspira Technologies Oxy B.H.N. Ltd</B></FONT></TD>
    <TD STYLE="padding-right: -4.5pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="padding-right: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[***]</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -4.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: -4.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: -4.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: -4.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: -4.5pt">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding-right: -4.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-right: -4.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; padding-right: -4.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -4.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="padding-right: -4.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="padding-right: -4.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: -4.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="padding-right: -4.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -4.5pt; width: 4%"></TD>
    <TD STYLE="padding-right: -4.5pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-right: -4.5pt; width: 31%">&nbsp;</TD>
    <TD STYLE="padding-right: -4.5pt; width: 20%">&nbsp;</TD>
    <TD STYLE="padding-right: -4.5pt; width: 4%">&nbsp;</TD>
    <TD STYLE="padding-right: -4.5pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="padding-right: -4.5pt; width: 31%">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -4.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-right: -4.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: -4.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: -4.5pt">&nbsp;</TD>
    <TD STYLE="padding-right: -4.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="padding-right: -4.5pt">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD>&nbsp;</TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>ea027176401ex99-1_inspira.htm
<DESCRIPTION>PRESS RELEASE ISSUED BY INSPIRA TECHNOLOGIES OXY B.H.N. LTD. ON JANUARY 5, 2026, TITLED "INSPIRA SIGNS TERM SHEET FOR ACQUISITION OF ADVANCED LIQUID BIOPSY CANCER DIAGNOSTICS TECHNOLOGY AND CONCURRENT $15 MILLION INVESTMENT AT $180 MILLION VALUATION."
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Inspira Signs Term Sheet for Acquisition of
Advanced Liquid Biopsy Cancer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Diagnostics Technology and Concurrent $15 Million Investment at $180 Million Valuation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>All-share acquisition positions Inspira to expand
into a multi-billion dollar diagnostics market</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>with a development-ready innovative technology; transaction structured to include significant</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>protections for existing shareholders of Inspira relating to its existing technologies</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">RA&rsquo;ANANA, Israel, January 5, 2026 -- Inspira&trade; Technologies OXY
B.H.N. Ltd. (NASDAQ: IINN) (&ldquo;Inspira&rdquo; or the &ldquo;Company&rdquo;), a pioneer in innovative life-support and diagnostic technologies,
today announced it has entered into a non-binding term sheet (the &ldquo;Term Sheet&rdquo;), outlining the principal terms of a proposed
two-part transaction that would include the acquisition of an advanced liquid biopsy diagnostics business, together with a concurrent
$15 million strategic equity investment into the Company, subject to the execution of definitive agreements (the &ldquo;Definitive Agreements&rdquo;).
The Company expects to finalize and execute the Definitive Agreements within approximately the next four weeks, following which the transaction
shall be subject to shareholder approval and customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">Dagi Ben-Noon, Chief Executive Officer of Inspira, commented &ldquo;We
are positioning the Company to expand into a high-growth diagnostics market through the planned acquisition of a development-ready liquid
biopsy platform, supported by a clear regulatory pathway, alongside a significant strategic equity investment of $15 million into the
Company that reflects a valuation framework driven by the technology&rsquo;s potential combined with our execution capabilities. Equally
important, the transaction has been structured to protect our existing shareholders, preserving their full economic upside to all future
realizations of value from our existing respiratory and blood monitoring technologies while providing exposure to a new diagnostics growth
opportunity.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Equity Investment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The proposed transaction includes a $15 million equity investment into
the Company, at a premium to the Company&rsquo;s current market capitalization, by a strategic investor (the &ldquo;Strategic Investor&rdquo;),
to be made concurrently with the closing of the Definitive Agreements, based on a pre-money valuation of the Company of $180 million.
The Company believes this proposed valuation reflects the Strategic Investor&rsquo;s independent assessment of the value and commercial
potential of the liquid biopsy technology combined with Inspira&rsquo;s existing technology and capabilities. The valuation marks a significant
premium over the Company&rsquo;s current market capitalization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">The identity of the Strategic Investor is expected to be disclosed
following shareholder approval and execution of the Definitive Agreements. As part of the transaction structure, Inspira intends to allocate
$12 million of the investment proceeds to fund the continued operations and development of its existing respiratory and blood monitoring
technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Strategic Acquisition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">As part of the proposed transaction, Inspira would acquire an advanced
liquid biopsy diagnostics business in an all-share acquisition. The acquisition would enable Inspira to enter the rapidly growing liquid
biopsy market through a proprietary platform (the &ldquo;Platform&rdquo;) designed to isolate and characterize circulating tumor cells
from standard blood samples. The Platform incorporates AI-powered cellular analysis intended to support cancer characterization and treatment
decision-making. In clinical validation studies conducted to date across dozens of patient samples, the Platform has demonstrated a high
level of concordance with traditional tissue biopsy, highlighting its potential to provide clinically meaningful insights that may complement
existing diagnostic approaches.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Platform&rsquo;s initial clinical focus is breast cancer, with
potential applicability across additional oncology indications. The global liquid biopsy market is projected to reach a market size of
approximately $58 billion over the coming decade<FONT STYLE="font-size: 10pt"><SUP>1</SUP></FONT>, driven by increasing demand for non-invasive
cancer detection and treatment monitoring. The acquired technology addresses a specific high-value segment, whole-cell characterization,
which provides diagnostic information beyond DNA or RNA-based sequencing approaches. Inspira brings established capabilities in blood-based
diagnostics, automation, and clinical execution that are directly applicable to liquid biopsy development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the acquisition, the Company expects to pursue U.S. Food
and Drug Administration (&ldquo;FDA&rdquo;) clearance for the liquid biopsy platform through the 510(k) regulatory pathway, leveraging
established regulatory precedents. Importantly, an existing reimbursement code is already in place for the intended clinical use, providing
a clear path to reimbursement upon regulatory clearance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Shareholder Protection Framework</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The proposed transaction would include a dedicated shareholder protection
framework designed to preserve the full economic upside of Inspira&rsquo;s existing respiratory and blood-monitoring platforms for current
shareholders, while simultaneously enabling participation in the growth potential of the liquid biopsy platform. Under this framework,
Inspira&rsquo;s shareholders of record at the completion of the Definitive Agreements are expected to receive contingent value rights,
ensuring that any future realization of value from Inspira&rsquo;s respiratory technology assets is allocated exclusively to the existing
shareholders. This structure is intended to allow Inspira to expand into a new diagnostics growth platform without diluting the economic
interests of its current shareholders in the Company&rsquo;s established respiratory and blood monitoring technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><SUP>1</SUP></FONT></TD><TD STYLE="text-align: justify">https://www.fortunebusinessinsights.com/liquid-biopsy-market-102506</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Inspira Technologies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B>Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood
monitoring solutions. The Company&rsquo;s FDA-cleared INSPIRA&trade; ART100 system is approved for cardiopulmonary bypass in the U.S.
and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA
ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies
is also advancing HYLA&trade;, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared
products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an
attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking
statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties
that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company
is using forward-looking statements when it discusses the potential execution of the Definitive Agreements, the timing thereof and the
need for shareholder approval for the proposed acquisition, the potential for the closing of the equity financing, the Company&rsquo;s
expansion into a high-growth diagnostics market through the planned acquisition of a development-ready liquid biopsy platform the anticipated
valuation of the Company, the potential benefits and advantages of strategic acquisition and establishment of a dual-platform medical
technology business, the anticipated timeline for the regulatory approval of the acquired liquid biopsy technology, the expected pursuit
of FDA clearance for the biopsy platform through the 510(k) regulatory pathway, the expected use of proceeds from the equity investment,
the shareholder protection framework and the expected issuance of contingent value rights and the Company&rsquo;s future operations and
strategic positioning following completion of the transaction. These forward-looking statements and their implications are based solely
on the current expectations of the Company&rsquo;s management and are subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company
undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting
the Company is contained under the heading &ldquo;Risk Factors&rdquo; in the Company&rsquo;s annual report on Form 20-F for the fiscal year
ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the &ldquo;SEC&rdquo;), which is available on the SEC&rsquo;s
website at www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Contact</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B></B>Inspira Technologies<BR>
Email: info@inspirao2.com<BR>
Phone: +972-9-9664485</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  C ) # 2(  A$! Q$!_\0
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MO2K^.2&2UN?LNK_'+XA64\B)/&CJSV\[-$Y0JWRN-RG)_=XV-D;S^T39VIU
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M@:);R0PV5O%)!I5C$\4&FR>=IT$;1P*R0V$W[VRC4A+63YX%C;FMN@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
